Cancer

Personal and Family History of Cancer and All-Cause Mortality

If you have had cancer, your long-term risk of dying from any cause is higher than someone who never had cancer. Close relatives with cancer can also raise your chances of getting cancer (and sometimes of dying from it), especially in cancers that run in families. That extra risk often comes from second primary cancers, treatment side effects, and shared genes or environments—but it can be lowered with smart follow-up care and healthy habits.

Key insights

Cancer survivors live longer than in past decades, but all-cause mortality remains higher than in people without cancer; the gap can persist for decades after diagnosis. [1] [2] [3] [4]
The size of the risk varies by cancer type, treatment exposures, time since diagnosis, and other health factors (heart health, mental health, fitness, metabolic risk). [5] [6] [7] [8] [12]
Family history signals inherited and shared risks; for some cancers (lung, gastric, colorectal, melanoma) it increases both incidence and mortality. For others (breast, prostate), family history does not necessarily worsen survival after diagnosis, likely due to earlier detection and better care. [1] [2] [3] [4] [5] [6] [7] [10] [11] [12] [13]
Modifiable factors matter a lot. Better cardiovascular health, physical function, and mental health are tied to lower all-cause mortality in survivors. [1] [7] [8] [12] [14] [15]

How much does risk increase?

Personal cancer history

Childhood, adolescent, and young-adult cancer survivors: roughly 4–6× higher all-cause mortality than the general population; excess risk lasts decades. [1] [2] [3] [4]
Breast cancer survivors: about 1.8× higher all-cause mortality vs. cancer-free women, with long-term elevation. [5]
Active cancer in older adults on hemodialysis: markedly higher all-cause mortality; remote past cancer may not raise risk in this group. [14]

Family cancer history

Lung, gastric, colorectal, and melanoma: family history increases both chances of developing cancer and dying from it. [1] [2] [3] [4] [5] [6] [7]
Breast cancer: for most non-BRCA carriers, family history does not worsen all-cause mortality after diagnosis. [10] [11] [12]
Prostate cancer: family history has been linked to better survival, likely due to earlier diagnosis and closer follow-up. [13]
Hereditary syndromes (e.g., BRCA1/2, Lynch): family history plus a pathogenic variant raises lifetime risk and may bring earlier onset, affecting mortality without careful prevention. [6]

Snapshot table: history and all-cause mortality

History factor	Typical impact on all-cause mortality	Notes	Citations
Childhood/AYA cancer survivor	~4–6× higher vs. general population	Persists for decades; driven by second cancers, CVD, late effects	[1] [2] [3] [4]
Breast cancer survivor	~1.8× higher vs. cancer-free women	Elevation persists years after diagnosis	[5]
Active cancer (elderly dialysis)	Higher vs. no cancer	Remote history may not add risk in this setting	[14]
Family history: lung/gastric/colorectal/melanoma	Higher incidence and mortality	Strength varies by site and age of onset	[1] [2] [3] [4] [5] [7]
Family history after breast cancer diagnosis	No clear worsening of all-cause mortality (non-BRCA)	Early detection and management help	[10] [11] [12]
Family history after prostate cancer diagnosis	Often better survival	Likely screening/lead-time effects	[13]

Why risk rises after cancer

Second primary cancers from shared risks or prior therapies. [1] [3] [8]
Treatment-related late effects, especially cardiovascular disease. [1] [12] [15]
Accelerated biological aging and reduced physical function. [7] [9]
Coexisting risks: hypertension, diabetes, smoking, obesity, low fitness, depression/anxiety, and high allostatic load. [6] [8] [10] [11] [12] [14] [15] [16]

What to do next: practical risk-lowering steps

Screening and surveillance

Follow oncology survivorship plans for second-cancer screening and treatment late-effects (e.g., tailored breast/colon screening; cardio-oncology follow-up for those exposed to anthracyclines or chest radiation). [1] [3] [5] [12]
With strong family history or early-onset cancers, consider genetic counseling and panel testing (BRCA1/2, Lynch, and others). [5] [6]

Cardiometabolic and lifestyle care

Aim for excellent cardiovascular health: control blood pressure, LDL-C, glucose; don’t smoke; stay active; maintain healthy weight; prioritize sleep. These behaviors are tied to lower all-cause mortality in survivors. [1] [12] [14] [15]
Build and maintain physical function with progressive aerobic and resistance training; better function is linked to lower mortality. [7]
Treat depression and anxiety; they independently predict worse outcomes. [6] [10]
Keep vaccinations and preventive care up to date.

Follow-up rhythm

See your primary care clinician at least annually; higher-risk survivors may need semiannual review.
Re-check risk factors (BP, A1c or glucose, lipid panel), review medications, and update screening intervals based on history and age.

Conclusion

Personal cancer history and, for many cancers, close family history increase all-cause mortality risk. That risk is not fixed. Early detection of second cancers, strong cardiovascular prevention, regular follow-up, fitness, and mental health care can meaningfully improve long-term survival—often more than family history alone would suggest.

Disclaimer: This article is for informational purposes only and not a substitute for medical advice.
Scientific summaries were compiled and synthesised using the AI models and peer-reviewed research.

References

Dixon S et al. The Lancet. 2023;401. https://doi.org/10.1016/S0140-6736(22)02471-0
Byrne J et al. International Journal of Cancer. 2021;150. https://doi.org/10.1002/ijc.33817
Suh E et al. The Lancet Oncology. 2020. https://doi.org/10.1016/S1470-2045(19)30800-9
Fidler-Benaoudia M et al. Journal of the National Cancer Institute. 2020. https://doi.org/10.1093/jnci/djaa151
Ramin C et al. Journal of the National Cancer Institute. 2020. https://doi.org/10.1093/jnci/djaa096
Jackson L et al. eClinicalMedicine. 2022;64. https://doi.org/10.1016/j.eclinm.2023.102159
Ezzatvar Y et al. Journals of Gerontology A. 2020. https://doi.org/10.1093/gerona/glaa305
Sud A et al. Journal of Clinical Oncology. 2017;35. https://doi.org/10.1200/JCO.2016.70.9709
Liu X et al. BMC Cancer. 2025;25. https://doi.org/10.1186/s12885-025-13760-6
Wang Y et al. Molecular Psychiatry. 2019;25. https://doi.org/10.1038/s41380-019-0595-x
Zhao J et al. Journal of the National Cancer Institute. 2024. https://doi.org/10.1093/jnci/djae223
Abramov D et al. Journal of the American Heart Association. 2024;13. https://doi.org/10.1161/JAHA.123.032683
Brook M et al. European Urology. 2022. https://doi.org/10.1016/j.eururo.2022.11.019
Cho H et al. Nephrology Dialysis Transplantation. 2023. https://doi.org/10.1093/ndt/gfad063d_5686
Mszar R et al. Circulation. 2025. https://doi.org/10.1161/cir.151.suppl_1.p1045
Iglay K et al. Journal of Clinical Oncology. 2017;35(36). https://doi.org/10.1200/JCO.2017.73.4947
Huang D et al. Gastric Cancer. 2024;27. https://doi.org/10.1007/s10120-024-01499-1
Kishida R et al. International Journal of Cancer. 2024;156. https://doi.org/10.1002/ijc.35191
Hemminki K et al. Cancers. 2021;13. https://doi.org/10.3390/cancers13174385
Matakidou A et al. British Journal of Cancer. 2005;93. https://doi.org/10.1038/sj.bjc.6602769
Lowery J et al. Cancer. 2016;122. https://doi.org/10.1002/cncr.30080
Chattopadhyay S et al. JNCI Cancer Spectrum. 2018;2. https://doi.org/10.1093/jncics/pky068
Chang E et al. Breast Cancer Research and Treatment. 2009;117. https://doi.org/10.1007/s10549-008-0255-3
Melvin J et al. Cancer Medicine. 2016;5. https://doi.org/10.1002/cam4.648
Lee M et al. International Journal of Cancer. 2017;140. https://doi.org/10.1002/ijc.30476